Podcasts about Teva Pharmaceuticals

On this episode of LID Radio Podcast, we're joined by Danny Gal to talk about his book The Belonging Paradox: How to Solve the Global Empathy Crisis.   About Danny Gal Danny Gal is a leadership coach and social entrepreneur with over 30 years of experience working with leading companies like HP, Monday.com and Teva Pharmaceuticals. He has facilitated transformative dialogues, including bridge-building efforts between Israelis and Palestinians and the 1,000 Roundtables Dialogue, which is Israel's largest public dialogue event.  About The Belonging Paradox In The Belonging Paradox, Danny Gal explores the transformative power of empathy and the art of staying together while embracing our differences. This book offers practical wisdom for building better lives, stronger organizations and more harmonious communities. 

On this episode of the "Gen AI Breakthrough" podcast, Nic Walden interviews Placid Jover, the Executive Vice President and Chief Human Resources Officer at Teva Pharmaceuticals. They discuss Placid's leadership philosophy, which emphasizes leveraging data and analytics to unlock the potential of individuals and teams within an organization. 

In this 20 minute podcast, Dr Emma Nash speaks to Dr Sally Higginbottom about adverse effects of antipsychotic medication, with a focus on movement disorders and strategies to detect them early in routine practice. Funding for this podcast was received from Teva Pharmaceuticals. Teva Pharmaceuticals reviewed the content for scientific accuracy and full editorial control remains the sole responsibility of the RCGP.

In this episode of The MedTech Talent Lab, Mitch Robbins sits down with Elena Mack, Chief Quality Officer at Sanisure, to discuss her career journey and insights into the world of quality and regulatory leadership in the medical device industry. With over 25 years of experience, Elena has held key executive roles at companies like Olympus, BD, and Teva Pharmaceuticals. Now, as part of Sanisher, she is leading the charge to build and maintain a world-class quality program for the bioprocessing and biomanufacturing sectors.Elena shares her early career experiences, including her shift from medical technology to microbiology and how she got started at Wyeth in a regulatory compliance role. She reflects on pivotal moments in her career, including taking on a leadership role as a director at ACUPAC and the invaluable lessons she learned about leadership, delegation, and the importance of empowering her team.Throughout the conversation, Elena also delves into the challenges of being a quality executive, emphasizing the responsibility of ensuring that quality is a shared value across all levels of an organization. She highlights the critical importance of having a robust quality system and talks about the ongoing efforts at Sanisher to move from ISO 9001 to ISO 13485, aiming to meet the highest standards of quality required by their customers.With her unique perspective on quality as a critical but often underappreciated function in the industry, Elena offers valuable insights into the role of quality professionals and how they can drive real impact within their organizations.Key Takeaways:The importance of leadership by example and empowering teams.The challenges and rewards of stepping into executive roles and delegating responsibilities.The need for robust quality systems in bioprocessing and biomanufacturing, especially in meeting regulatory standards.Elena's personal connection to quality through her experiences with her son's health challenges.Links:Elena on Linkedin https://www.linkedin.com/in/elena-mack-bb57855/Sanisure Website www.sanisure.com

You cannot get a patent if your invention is obvious. This can be tricky to determine for biotech and pharmaceutical patents. There are competing standards for how this is determined. One is the "reasonable expectation of success" standard, which is a lower threshold than the "predictable results" standard. The Supreme Court refused to hear a case that would have settled this, so we're left with the Federal Circuit's ruling in the case of Vanda Pharmaceuticals vs. Teva Pharmaceuticals. Listen to this episode to learn how these tests can give different results for patentability and what it means for the future biotech and drug patents!

The Daily Business and Finance Show - Thursday, 26 December 2024 We get our business and finance news from Seeking Alpha and you should too! Subscribe to Seeking Alpha Premium for more in-depth market news and help support this podcast. Free for 14-days! Please click here for more info: Subscribe to Seeking Alpha Premium News Today's headlines: Apple can't rely on Google, wants to testify at Search antitrust trial in April - report Tesla rallies into Christmas break as Q4 deliveries report looms Vermilion Energy to buy Alberta oil and gas producer Westbrick in C$1.07B deal American Airlines grounds all flights due to technical issues Biden to decide on US Steel takeover after CFIUS deadlocks Nasdaq 100 rebalance: Meta, Broadcom and Tesla index weighting reduced All eyes on Netflix as Christmas NFL games take the spotlight Bitcoin ETF declares monthly distribution of $1.1131 Teva Pharmaceutical shares surged for seven straight sessions Explanations from OpenAI ChatGPT API with proprietary prompts. This podcast provides information only and should not be construed as financial or business advice. This podcast is produced by Klassic Studios Learn more about your ad choices. Visit megaphone.fm/adchoices

The Daily Business and Finance Show - Wednesday, 25 December 2024 We get our business and finance news from Seeking Alpha and you should too! Subscribe to Seeking Alpha Premium for more in-depth market news and help support this podcast. Free for 14-days! Please click here for more info: Subscribe to Seeking Alpha Premium News Today's headlines: Tesla rallies into Christmas break as Q4 deliveries report looms Major banks sue Federal Reserve over stress testing framework OpenAI ponders humanoid robot in quest to take AI to new level: report Apple can't rely on Google, wants to testify at Search antitrust trial in April - report American Airlines grounds all flights due to technical issues (updated) Teva Pharmaceutical shares surged for seven straight sessions British American Tobacco snaps six straight sessions of losses U.S. home prices record smallest Y/Y rise since October 2023, Redfin says Explanations from OpenAI ChatGPT API with proprietary prompts. This podcast provides information only and should not be construed as financial or business advice. This podcast is produced by Klassic Studios Learn more about your ad choices. Visit megaphone.fm/adchoices

In dieser Episode spreche ich mit Timo Buck, Head of Applied Data Science & AI, Teva Pharmaceuticals. Wir sprechen über folgende Themen: Wie helfen Daten dabei, Künstliche Intelligenz erfolgreich einzusetzen? Welche Rolle spielt Data Governance in der KI-Nutzung? Welche Rolle spielt das Top-Management bei der Einführung von KI? Wie bringt man KI-Systeme dazu, echte Mehrwerte zu liefern? Welche Sicherheitsrisiken gibt es bei generativer KI? Warum ist das Mindset von Mitarbeitenden für KI so wichtig? Erhalte jede Woche aktuelle Strategien in dein E-Mail Postfach: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.stateofprocessautomation.com/ Podcast-Moderator: Christoph Pacher LinkedIn Interviewgast: Timo Buck, Head of Applied Data Science & AI, Teva Pharmaceuticals LinkedIn

Guest: Meet Dr. Phillip Frost: Billionaire CEO and the Healthcare Pioneer Behind OPKO Health $OPK Website: https://www.opko.com/ Ticker: $OPK His Wikipedia page: https://en.wikipedia.org/wiki/Phillip_Frost Bio: Dr. Frost has been the CEO and Chairman of OPKO since March 2007. Previously, Dr. Frost served at Teva Pharmaceutical industries, Limited (“TEVA”) as both Chairman of the Board and Vice Chairman. Dr. Frost served as Chairman of the Board of Directors and CEO of IVAX Corporation from 1987 until its acquisition by Teva in January 2006. He also served as Chairman for Key Pharmaceuticals, Ladenburg Thalmann Financial Services was a director of Continucare Corporation and Castle Brands, Inc. He was also a Governor and Co-Vice-Chairman of the American Stock Exchange. Dr. Frost is a past chairman and currently serves as a member of the Board of Trustees of the University of Miami, the Shanghai Institute for Advanced Immunochemical Studies in China, and as a Trustee of the Miami Jewish Home for the Aged and the Mount Sinai Medical Center. He also serves as a member of the Executive Committee of the Phillip and Patricia Frost Museum of Science. He is a past member of the Board of Trustees of the Scripps Research Institute, the Board of regents of the Smithsonian Institution, and the Skolkovo Foundation Scientific Advisory Council in Russia. Dr. Frost is a director of Cocrystal Pharma Inc, a publicly traded biotechnology company developing new treatments for viral diseases. --- Support this podcast: https://podcasters.spotify.com/pod/show/smartmoneycircle/support

Synopsis: In this insightful conversation on Biotech2050, host Rahul Chaturvedi sits down with Bharatt Chowrira, CEO, and Eric Elenko, Co-Founder and President of PureTech Health. They explore the company's pioneering R&D model and how it reshapes drug development by focusing on solving specific problems rather than pushing predefined solutions. Bharatt and Eric share their professional journeys and key insights, emphasizing the importance of simplicity and unwavering commitment to impactful ideas. The episode delves into the story behind Karuna Therapeutics, highlighting the challenges of obtaining funding and skepticism from the industry before its success with a groundbreaking schizophrenia drug. Bharatt and Eric underline the importance of patient-centered innovation and reflect on the lessons learned, including overcoming obstacles with persistence. They also discuss the need for more efficient pathways in drug development and share a glimpse into PureTech's upcoming projects. Biography: Bharatt Chowrira, PhD, JD, is the chief executive officer and a member of the board of directors at PureTech. Dr. Chowrira has been a member of the PureTech management team since March 2017, leading various departments including Operations, Finance and Business Development. Dr. Chowrira plays a key role in the Founded Entity fundraisings and provide strategic guidance as a Board member to many Founded Entities, including co-founding Seaport Therapeutics. Prior to joining PureTech, he held various leadership roles including Chief Executive Officer, President, Chief Operating Officer and General Counsel in multiple biotech companies over the past 30+ years, including Auspex Pharmaceuticals Inc., which was acquired by Teva Pharmaceuticals for $3.5 billion and Sirna Therapeutics that was acquired by Merck for $1.1 billion and as a Vice President at Merck & Co. Dr. Chowrira received a JD from the University of Denver's Sturm College of Law, a PhD in molecular biology from the University of Vermont College of Medicine, an MS in molecular biology from Illinois State University and a BS in microbiology from the UAS, Bangalore, India. Eric Elenko, PhD, is the president at PureTech where he has led the development of a number of programs, including three that have received US FDA approvals (EndeavorRx, Plenity and Cobenfy). Dr. Elenko plays a key role in the Founded Entity drug discovery and fundraisings, including co-founding Seaport Therapeutics. Prior to joining PureTech, Dr. Elenko was a consultant with McKinsey and Company where he advised senior executives of both Fortune 500 and specialty pharmaceutical companies on a range of issues such as product licensing, mergers and acquisitions, research and development strategy and marketing. Dr. Elenko received his BA in biology from Swarthmore College and his PhD in biomedical sciences from the University of California, San Diego.

No discussion regarding the future is complete unless AI is incorporated. In this episode, Konstantina Katcheves of Teva Pharmaceuticals and Sanskriti Thakur of TOWER Capital Group provide their insights on the impact of not only the benefits of the technology but the regulatory challenges and uncertainty surrounding AI. Host ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, Head of Insights, BioSpace Guests Konstantina Katcheves, Senior Vice President, Innovative Medicines Global Business Development and Acquisitions, Teva Pharmaceuticals Sanskriti Thakur, Chairwoman, TOWER Capital

In this CME episode, Dr. Andy Cutler interviews Dr. Leslie Citrome about the impact of tardive dyskinesia on patient-reported outcomes and quality of life. They discuss how to correctly assess and diagnose tardive dyskinesia, as well as effective management strategies that incorporate the individual needs of patients.  Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Understand the physical, psychological, social, and occupational impacts of tardive dyskinesia (TD) on patients Identify clinical tools and patient-reported outcome measures to assess the severity and impact of TD Formulate evidence-based treatment strategies for TD that enhance patient outcomes and quality of life Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.   Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 1 hour Released: October 23, 2024*   Expiration: October 22, 2027 *NEI maintains a record of participation for six (6) years.   CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-TD   Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 1.0 ANCC contact hour Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.0 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.0 contact hour (.10 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.0 AAPA Category 1 credit. Approval is valid until OCtober 22, 2027. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1 general continuing education credits. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Leslie Citrome, MD, MPH Clinical Professor, Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY Consultant/Advisor: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, Clinilabs, COMPASS, Delpor, Eisai, Enteris BioPharma, HLS Therapeutics, Idorsia, INmune Bio, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Luye, Lyndra, MapLight, Marvin, Medavante-ProPhase, Merck, Mitsubishi-Tanabe Pharma, Neumora, Neurocrine, Neurelis, Noema, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sumitomo/Sunovion, Supernus, Teva, University of Arizona, Vanda Speakers Bureau: AbbVie/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, Eisai, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda, Teva Stockholder: Bristol-Myers Squibb, Eli Lilly, J & J, Merck, Pfizer, Reviva (options) The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O'Brien, Gabriela Alarcón, PhD, Andrea Zimmerman, EdD, CHCP, and Brielle Calleo. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported by an unrestricted educational grant from Teva Pharmaceuticals.

Tuesday October 22, 2024 Teva Pharmaceuticals to Pay $450 Million to Settle False Claims Charges

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Stacy Finkbeiner, PhD Guest: Bill Cote To gain insights into how tardive dyskinesia (TD) can impact the physical, psychological, social, and professional lives of patients, the IMPACT-TD Registry incorporated feedback from patients and caregivers to create an effective questionnaire. These patient-reported measures are key to the overall management of TD as they enable us to better understand how TD affects each individual. To learn more about the patient-reported outcomes from the IMPACT-TD Registry, Dr. Charles Turck speaks with Dr. Stacy Finkbeiner and Mr. Bill Cote. Dr. Finkbeiner is US Medical Director at Teva Pharmaceuticals, and Mr. Cote is the Senior Director of the National Organization for Tardive Dyskinesia.

Host: Ashley Baker, MSN, PMHNP Guest: Stacy Finkbeiner, PhD The IMPACT-TD Registry is an ongoing, real-world observational study that aims to better understand the multidimensional impacts of tardive dyskinesia (TD) on patients' lives. To achieve this goal, the IMPACT-TD Scale was developed and used by clinicians involved with the study, and now the results from the interim analysis are available. Joining psychiatric nurse practitioner Ashley Baker to share the key findings on TD's impact from the clinician perspective is Dr. Stacy Finkbeiner, U.S. Medical Director at Teva Pharmaceuticals.

Lauren Holder recently did a webinar with HDYO's Jenna Heilman, Prof. Hugh Rickards, and HDYO Ambassador Molly about breaking down barriers when it comes to access to a potential treatment. You can watch the full video here: https://www.youtube.com/watch?v=y6CrrVGfBTk Breaking Down Barriers is sponsored by Roche, Sage Therapeutics, Teva Pharmaceutical, uniQure, Wave Life Sciences, The Griffin Foundation, Neurocrine Biosciences and PTC Therapeutics.

#201 What Does a Best in Class Finance Team Look Like? with Sharon Barber-Lui, CFO, Teva Pharmaceuticals https://open.spotify.com/episode/0VINqaQdff5glvnpFNcKm4 In this episode, we have the privilege of diving deep into the remarkable career journey of Sharon Barber-Lui, the Chief Financial Officer of Teva Pharmaceuticals. Sharon's path from her roots in public accounting to leading a diverse team of 200 finance professionals at a global pharmaceutical company is nothing short of inspiring. As someone who has successfully navigated the complexities of the finance world, Sharon has amassed a wealth of knowledge on building high-performing teams. She emphasizes the foundational role of trust and a shared sense of purpose, as well as the relentless pursuit of continuous improvement, as cornerstones of effective leadership. Sharon's insights don't stop there; she passionately advocates for finance leaders to transcend traditional roles and become strategic business partners. In her view, this involves harnessing cutting-edge technologies such as artificial intelligence and predictive analytics to not only streamline processes but to add tangible value to the business. She also champions the importance of diversity and inclusion in the workplace, urging leaders to broaden their candidate pools and engage in active outreach to cultivate a rich tapestry of perspectives and ideas. Throughout this episode, Sharon shares her perspectives on the evolving role of the CFO as a strategic force within a company. She underscores the importance of delivering results while fostering a culture of innovation and collaboration. Join us as we explore how these principles can be applied to drive success in an ever-changing business landscape. Whether you're an aspiring finance professional or a seasoned leader, Sharon's experiences and insights offer invaluable lessons in leadership and growth. Key topics covered include: Sharon's career journey from public accounting to Merck and then to a small biotech company Her transition to the CFO role at Teva Pharmaceuticals and the structure of her 200-person finance team Challenges of managing a large finance team and creating a high-performing culture Defining the characteristics of a "best-in-class" finance team, including trust, shared purpose, and continuous improvement Sharon's strategic priorities and leadership style when joining Teva Pharmaceuticals The importance of effective business partnering and connecting finance to the broader business Leveraging technology and analytics, including the role of AI, to drive insights and decision-making Emphasis on diversity and inclusion in building a high-performing finance team Strategies for finance teams to get involved in strategic discussions and decision-making The evolving role of the CFO and critical skills needed for the future https://youtu.be/gLEdvD20oYw Links Sharon Barber-Lui on LinkedIn Kevin Appleby on LinkedIn GrowCFO Mentoring Timestamps 0:00:12 - Introduction of Sharon Barber-Lui, CFO of Teva Pharmaceuticals 0:00:44 - Sharon's career journey from public accounting to Merck and then a small biotech company 0:03:32 - Transition to Teva Pharmaceuticals and the structure of her 200-person finance team 0:04:55 - Challenges of managing a large finance team and creating a high-performing culture 0:07:50 - Defining the characteristics of a "best-in-class" finance team 0:10:02 - Distinction between a "high-performing team" and a "best-in-class" team 0:11:00 - Importance of effective business partnering and connecting finance to the broader business 0:15:40 - Leveraging technology and analytics, including the role of AI 0:19:40 - The evolving role of the CFO and critical skills needed for the future 0:21:26 - Emphasis on diversity and inclusion in building a high-performing finance team

In dieser Episode spreche ich mit Corina Zilch-Schuler, Associate Director und Global Digital Commercial Operations Lead bei Teva Pharmaceuticals. Wir sprechen über folgende Themen: Was ist Citizen Development? Wie führe ich Citizen Development in meinem Unternehmen ein? Welche Vorteile hat Citizen Development für Unternehmen? Was sind Low-Code- und No-Code-Tools? Wie kann Citizen Development die digitale Transformation fördern? Welche Risiken gibt es bei Citizen Development? Wie erstellt man ein Governance-Modell für Citizen Development? Welche Schulungen sind notwendig für Citizen Development? Für welche Projekte eignet sich Citizen Development am besten? Wie skaliere ich Citizen Development in meinem Unternehmen? Welche Fehler sollte man bei Citizen Development vermeiden? Welche Tools eignen sich am besten für Citizen Development? Wie unterstützt Citizen Development agile Softwareentwicklung? Was sind die Auswirkungen von Citizen Development auf IT-Teams? Wie messe ich den Erfolg von Citizen Development? Welche zukünftigen Trends gibt es im Bereich Citizen Development? Erhalte jede Woche aktuelle Strategien in dein E-Mail Postfach: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.stateofprocessautomation.com/ Podcast-Moderator: Christoph Pacher LinkedIn Interviewgast: Corina Zilch-Schuler, Associate Director, Global Digital Commercial Operations Lead bei Teva Pharmaceuticals LinkedIn

“Sustainability is not just a trend; it's integral to our DNA,” says Teva's Global Head of Sustainability Amalia Adler-Waxman, SVP, Global Head of Sustainability and ESG and head of Corporate Affairs of International Markets at Teva Pharmaceuticals Industries, brings a wealth of experience from her roles in government, international affairs organisations, and the pharmaceutical industry. Her unique perspective bridges the gap between public and private sectors, offering invaluable insights into the evolving landscape of corporate sustainability. Amalia Adler-Waxman's journey with Teva began in 2016 as a consultant. Since then, she has led the company's transformation into one of the ‘World's Most Sustainable Companies', as recognised by Time magazine. In the latest PharmaSource podcast episode, Amalia explains how Teva's commitment to sustainability has become a key strategy for driving positive impact and improving business performance.

In der heutigen Folge von „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über Kursziel 0 bei Mynaric, wie viel es braucht, um reich zu gelten und Boom bei Zoom. Außerdem geht es um Siltronic, Lanxess, Befesa, Adidas, Snowflake, Zoom, MongoDB, Cloudflare, Datadog, Wolfsspeed, Northrop Grumman, L3Harris, Covestro, K+S, BASF, Knorr-Bremse, Fresenius Medical Care RTL Group, ARK Space Exploration&Innovation ETF (WKN: A3CUNY), Goldman Sachs Hedge Industry VIP ETF (WKN: A2DWAV), Adobe, Caesars Entertainment, Endeavor Group Holdings, Spotify, IAC, HashiCorp, Insmed, Teva Pharmaceutical, Natera, GE Vernova, UnitedHealth Group, Hubspot,Workday, Vistra, Walt Disney, Amphenol, Constellation Energy, Stericycle, Teleflex, Paylocity, Nvidia, Netflix, Eli Lilly, Apple, Broadcom, TMSC, Tenet Healthcare, Progressive, Sea, MercadoLibre, Carrier Global, Hitachi, Midea, Haier Smart Home, Whirlpool und Samsung. Wir freuen uns an Feedback über aaa@welt.de. Ab sofort gibt es noch mehr "Alles auf Aktien" bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Michigan's local governments have until Aug. 12 to request funds from the $1.2 billion National Kroger Settlement on opioid abuse. The Great Lakes state is expected to receive $42 million over the course of 11 years. Eligible communities, at the city or county level, can apply for the funding to be used toward drug abuse treatment. Agreements are expected to be effective by early fall. Michigan previously received more than $1.6 billion in settlement funds from Allergan Pharmaceutical, CVS, Janssen Pharmaceuticals, McKinsey & Co., Publicis, Teva Pharmaceutical, Walgreens and Walmart.Support this podcast: https://secure.anedot.com/franklin-news-foundation/ce052532-b1e4-41c4-945c-d7ce2f52c38a?source_code=xxxxxxFull story: https://www.thecentersquare.com/michigan/article_c118cca4-55be-11ef-9444-5f3465fd5010.html

In today's episode of the HR Leaders Podcast, we are joined by Aurélien Mamou, SVP, Human Resources, Teva Global Operations at Teva Pharmaceuticals.Aurélien shares his journey from global consulting to leading HR at Teva Pharmaceuticals. He reveals how empathy and inclusive leadership can transform company culture, and shares insights on strategic HR management to enhance efficiency and reduce costs.Aurélien also delves into the importance of organizational development and the personal strategies he uses to maintain a growth mindset and continuous learning.

Timestamps: 8:49 - Pivoting your marketing 12:17 - The key ingredients for sports recovery 17:43 - Distributing through several channels  23:22 - Importing CONDA to Switzerland  33:25 - Developing crowdfunding momentum  This episode was co-produced with CONDA.ch. If you want to invest in CONDA.ch with preferential conditions, contact them at investor@conda.ch. About Pedro Schmidt & Linus Gabrielsson: Pedro Schmidt is the founder and CEO of KaEx, the world's first sports-recovery drink to significantly reduce the stress hormone. He holds a MSc in Management, Technology and Economics from ETH Zürich, and previously worked for companies like Siemens Management Consulting, Bristol-Myers Squibb and Teva Pharmaceuticals before founding KaEx in 2016.  Linus Gabrielsson is the managing director at CONDA.ch, the leading platform providing Swiss startups access to crowd investment capital as well as community building and campaigning opportunities. He holds a MSc in Technology Management from ETH and previously worked for companies like IBM Business Consulting Services, PwC and HSBC Private Bank before founding CONDA.ch in 2021. KaEx was the result of many years of research for Pedro, whose undergraduate education is in Pharmaceutical Sciences. He originally branded it as a hangover remedy, and that's how it began to be sold in pharmacies and at Coop supermarkets. At some point, Pedro and his team started getting messages from people who swore on the benefits of drinking KaEx post-workout. Pedro ignored these messages at first, since as a resource-constrained founder he couldn't afford to split his focus — but then pro-athletes started contacting him as well, asking if drinking KaEx could be considered doping (which it couldn't). This made Pedro and his team seriously question whether they should pivot their product's branding and focus. They eventually did do so, and nowadays KaEx is known primarily as a sports drink, though it is of course also useful for hangovers or after a particularly stressful day. In 2021, CONDA.ch was already one of the most successful crowdfunding platforms in Austria and Germany. Rather than try to compete with them, Linus and his co-founder Christian Klumpe decided to strike a franchising deal with their DACH counterparts in order to bring CONDA to Switzerland. As a crowdfunding platform, they focus on startups, SMEs and real estate, and allow users to invest as little as CHF 100. CONDA.ch always runs a 2 week pre-round with preferential conditions open only to VIP investors: that way, when the deal goes public, it never starts at 0, which helps it gain momentum. KaEx has crowdfunded on CONDA.ch several times.  

Henssler Money Talks – April 27, 2024Season 38, Episode 17This week on “Money Talks,” Chief Investment Officer Troy Harmon, CFA, CVA, is joined by fellow Research Analysts Nick Antonucci, CVA, CEPA, and Jacob Keen, CFA, to cover the week's market action and the first reading of First Quarter 2024 GDP. The Analysts take a deeper dive into the trends seen in the stock market, economy, and the possibility of stagflation. The show hosts round out the show by answering listeners' questions, including one about Teva PharmaceuticalsTimestamps and Chapters0:00 Market Roundup: April 22 – April 26, 202422:56 Case Study: Trends in the Economy and Stock Market 33:38 Q&A Time: Stagflation and Teva PharmaceuticalsFollow Henssler:  Facebook: https://www.facebook.com/HensslerFinancial/ YouTube:  https://www.youtube.com/c/HensslerFinancial LinkedIn: https://www.linkedin.com/company/henssler-financial/ Instagram: https://www.instagram.com/hensslerfinancial/ TikTok: https://www.tiktok.com/@hensslerfinancial?lang=en X: https://www.x.com/hensslergroup  “Money Talks” is brought to you by Henssler Financial. Sign up for the Money Talks Newsletter: https://www.henssler.com/newsletters/ 

Explore the future of healthcare transformation guided by Dawn Sherman, CEO of LabConnect, a trailblazer in clinical trials. The dialogue extends to the synergy of Quantum Computing and Artificial Intelligence, revolutionising conventional trial approaches. Delving into the profound implications of rejuvenation technologies, Don contemplates their societal impact. Join this conversation for a profound journey into healthcare innovation, leadership, and the evolving landscape of clinical trials. [00:10] - About Dawn Sherman Dawn is the CEO of LabConnect. She has held various leadership positions in companies such as ProPharma Group, EnvisionRxOptions, Teva Pharmaceuticals, Medco Health Solutions, and Hay Group. She also serves on several boards within the life sciences focused on services to pharmaceutical, biotechnology, and medical device companies.  --- Support this podcast: https://podcasters.spotify.com/pod/show/tbcy/support

Carl Quintanilla and Sara Eisen tackle today's biggest Money Movers from the floor of the New York Stock Exchange. 

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. ## Insulet CFO, Wayde McMillan, has left the company to join 3M's health spinoff. Baxter has hired a new CFO, Joel Grade, who previously worked in the food industry at Sysco for 25 years. Akura Medical has secured $35 million in funding to pursue FDA clearance for its thrombectomy device. Duke researchers have found that an app improves autism screening in a study funded by the NIH. Invitae's test for hereditary cancers has gained FDA de novo approval. The FDA has expanded its total product life cycle program to cover neurological devices and could enroll up to 45 additional devices over the next year.In other news, Lilly has announced changes to its executive team, with Mike Mason retiring and being replaced by Patrik Jonsson. Novartis has completed the spinoff of its generic drug unit, Sandoz. Sanofi will pay $500 million to collaborate with Teva on the development of an anti-gut disease therapy called TL1A. Moderna has claimed positive results in an early study for its combination COVID-19 and flu vaccine. A new report shows that only two out of eight biotech companies that priced offerings since July 1 are currently trading at or above their debut share price.Moving on to healthcare industry news, Kaiser Permanente workers have initiated the largest strike in history. Progressive lawmakers Elizabeth Warren and Pramila Jayapal have called for closer examination of the $3.3 billion deal between UnitedHealth and Amedisys. A report from Fitch Ratings suggests that nonprofit hospitals will continue to face labor-related challenges. Molina has lost the anticipated Indiana Medicaid contract.French pharmaceutical company Sanofi has signed a potential $1.5 billion deal with Teva Pharmaceuticals. The FDA has raised concerns about Amgen's confirmatory trial for its lung cancer drug Lumakras. Ten companies have registered to participate in Medicare's drug price negotiation program. Regeneron and Intellia are expanding their collaboration on CRISPR/Cas9 gene editing. Eli Lilly is deepening its oncology pipeline with the acquisition of Point Biopharma. Boehringer is offering an unbranded biosimilar at an 81% discount to AbbVie's Humira. Several biopharmaceutical companies have recently implemented layoffs. The FDA has rejected Lilly's eczema treatment.Investors are funding longevity companies that focus on developing therapeutics to interfere with the aging process. Some companies have managed to secure funding despite a decline in investment in the sector. Ten companies have registered to participate in the Medicare drug price negotiation program. Eli Lilly is shuffling its executive team as it awaits FDA approval for its weight loss drug. The

Janssen Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc.

Within about five minutes of conversation with Protalix CFO Eyal Rubin, I learned that he doesn't bite his tongue about the rigors of biotech business and finance management, which is precisely why I'm eager to talk with him on today's episode of the podcast. From commercialization deals with big pharma to being about $50 million underwater to swatting away the day trading armchair quarterbacks on Stocktwits, Rubin's seen a few things and he's developed more than a few opinions. On this episode of the Business of Biotech, you'll get a front-row seat to a discussion with a biotech CFO who knows how to put on the blinders, shut out distractions, right the ship and set the course to favorable financial waters. Bringing his years of experience in the CFO role at Teva Pharmaceuticals, Brainstorm Cell Therapeutics, and now, Protalix Biotherapeutics, we bring you Eyal Rubin for a story on big biopharma fiscal recoveries. Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!

In today's episode, Ashanti Bentil-Dhue welcomes Tina Gilbert, the Managing Director of Advisory Services at Management Leadership for Tomorrow (MLT). MLT is a distinguished organisation in the U.S. that strives to elevate African Americans, Hispanic Latinx, and Native Americans into roles that foster their growth and leadership. Tina's pivotal role is ensuring the recipient organisations have the right policies, practices, and culture in place to help these individuals thrive. In this episode, she shares valuable insights into how companies can create cultures of equity even during a recession, and the importance of strategic planning, understanding DEI practices, negotiation, communication, and influence in this process. Tune in to hear Tina discuss the importance of empathising with lived experiences and empowering others, creating a potent narrative around what makes a truly inclusive and equitable environment. “ Especially in my role as a managing director, where I have people underneath me who are spending the day with the employers working with them, it is how are you empowering those beneath you, across from you and with you. So you are not doing this alone. This can be a very lonely job, and especially in this time of economic transition, where you might be the only one who has the formal title of D&I. And so what are you doing both formally and informally, to bring others along on this journey with you. So you are not alone, I spent a lot of time talking about the level of engagement that you need to be able to bring and have with individuals, so that you are growing kind of your force, the people that are working with you, for you and beside you. And so in these times where it might get harder and harder to get the people formally on your team, what are you doing to empower those through volunteerism, through champion through sponsorships, so you're not in this alone. ” Episode Highlights:  ● Dig into the lived experiences of the populations you work with ● The business case for diversity, equity and inclusion ● Developing skills and competencies in the field About Tina Gilbert:   Tina Gilbert (she / her)  is the Managing Director of Advisory Services responsible for delivery of client services and development of Diversity, Equity, Inclusion leading practices and insights.  Tina brings 10 years of DEI Leadership (4 years global), 15 years of Strategic Consulting, and 25 years of corporate experiences across six industries to this role. Throughout her career, she has led efforts to transform organizations' operating models, business processes, and employee culture to create measurable impact. As an I&D Leader over the last ten years, she has partnered with Business and HR leaders in designing strategies and metrics that align with talent strategies and desired business outcomes. Prior to joining MLT, Tina was the Inclusion and Diversity Leader for Teva Pharmaceuticals and Accolade (Healthcare Navigation and Data). As the first I&D leader at both organizations, she guided each organizations' evolution from diversity compliance management to recognizing its value as a business imperative. Her work at Teva was recognized in 2017 by Diversity Inc. Magazine as one of their Noteworthy Companies. More recently she was named as one of Hive Learning's Most Influential D&I Leaders and by FindSpark as one of the 30 Must-Follow Diversity & Inclusion Thought Leaders Transforming the Workplace. Before working as a full-time Diversity Practitioner, Tina was a Partner/Managing Director with Accenture's Strategy Practice leading large transformation projects, business strategic planning programs, and operations/organizational design.  At Accenture, she sponsored a variety of DEI programming, recruiting and training initiatives. She holds a BS from Spelman College, an Industrial Engineering degree from the Georgia Institute of Technology, and an MBA from The Wharton School, University of Pennsylvania.  She is based out of the Philadelphia, PA area.   If you would like to apply to be a guest on the show email: operations@goodsoilleaders.com   If you would like to schedule a capability briefing call with our team, email: operations@goodsoilleaders.com    If you would like to apply for DEI PRO Coaching, email: operations@goodsoilleaders.com  Stay Connected with Ashanti:  LinkedIn: Ashanti Bentil-Dhue   

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. Diabetes device companies Dexcom and Abbott are increasing their direct-to-consumer marketing efforts as they compete for a larger share of the growing diabetes market. With insurers now covering continuous glucose monitors for more people, device-makers are adopting strategies commonly used by pharmaceutical companies to promote their products.Agilent Technologies has announced plans to wind down its Resolution Bioscience liquid biopsy unit. The company will discontinue operations at the business it acquired two years ago for $550 million.Tandem Diabetes Care's Chief Commercial Officer, Brian Hansen, is resigning ahead of the company's upcoming rollout of its new insulin pump, called the Mobi Pump.Google Cloud's Amy Waldron discussed the tech giant's ambitions in healthcare and the potential risks associated with generative artificial intelligence (AI) in the industry. Generative AI has the ability to create new content, such as images and text, but there are concerns about the ethical implications and potential biases that may arise.The Washington Post reports on the changing landscape of healthcare delivery, with state laws allowing non-doctors to treat patients. AP News highlights the mental health challenges faced by survivors of the Maui wildfire. The CDC is working to overhaul its lab operations following issues with COVID-19 testing. Medical Device and Diagnostic Industry explores the use of plastic in medical devices and its environmental impact.Gilead Sciences has faced another setback with its cancer drug, as the FDA partially halted leukemia studies of the drug. This drug was the center of Gilead's $5 billion acquisition of biotech company Forty Seven in 2020.Regeneron Pharmaceuticals rebounded by winning FDA approval for a longer-lasting vision loss drug called high-dose Eylea. The drug was cleared less than two months after it was initially rejected by the FDA. Additionally, the agency also approved a separate Regeneron drug for an ultra-rare disease.The FDA expanded the use of a neurocrine drug called Ingrezza to include Huntington's disease patients with a movement disorder known as chorea. This approval is expected to intensify the commercial battle between neurocrine and Teva Pharmaceuticals.Genesis, a California startup focused on AI drug discovery research, raised $200 million in a series B funding round. The total funding for Genesis now exceeds $280 million

One day Teva will be able to prevent an asthma attack from ever happening again. Manny Montalvo talks about the transformation in the pharmaceutical sector and the digital innovations Teva is implementing by infusing medication and technology, specializing in respiratory care. He also speaks about the collaborative approach the company is taking by partnering with other tech and pharmaceutical companies to increase patient reach, improve the technology, and deliver an entire ecosystem that supports patients' journeys. Tune in to learn how the pharmaceutical sector is evolving and how Teva Pharmaceuticals embraces this transformation! Click this link to the show notes, transcript, and resources: outcomesrocket.health

If you're feeling comfortable in your treasury role, could it be time to move on? This week's podcast guest thinks it's definitely worth considering. His fast-paced career has seen him challenge himself across the globe in a number of different roles. On episode 271 of The Treasury Career Corner, we are joined by Michael McCartin, Director of Treasury at Curaleaf. Michael shares his exciting career journey, experiences working abroad and how he built a treasury function from the ground up. Plus, he talks about why communication is paramount (especially in remote roles) and his secrets behind building a solid reputation. Michael's treasury career first started as a Treasury Analyst with David's Bridal in 2003 before a stint as Financial Analyst at Catapult Learning. Following a short time with Morgan Lewis & Bockius, Michael joined Preferred Sands as a Cash Accountant and then teamed up with Teva Pharmaceuticals as Senior Treasury Analyst, later working his way to the Treasury Manager role. Since 2018, Michael has managed treasury functions at SICOM Systems Inc., SUEZ, LifeScan and NOVAVAX INC. He currently works as Director of Treasury at Curaleaf, a New York-based cannabis company. On the podcast we discussed… Michael's treasury origin story His transition from treasury analyst to group treasurer The ups and downs of working abroad How Michael adapted to remote working Why no-one knowing your name means you're succeeding How his career hit new heights at Teva Pharmaceuticals Launching a treasury function from scratch The importance of communication in treasury The best ways to enhance your reputation You can connect with Michael McCartin on LinkedIn. Are you interested in pursuing a career within Treasury? Whether you've recently graduated, or you want to search for new job opportunities to help develop your treasury career, The Treasury Recruitment Company can help you in your search for the perfect job. Find out more here. Or, send us your CV and let us help you in your next career move! If you're enjoying the show please rate and review us on whatever podcast app you listen to us on, for Apple Podcasts click here! If you're interested in learning more about the fundamental pillars of treasury, download my free Corporate Treasury eBook by clicking here!

The gaps in health equity can inform where there's a need for digital health technologies. In this episode of the Straight Out of Health IT podcast, Chris interviews Tanisha D. Hill, Respiratory and Digital Health Medical Lead at Teva Pharmaceuticals, Senior US Medical Director, and Founder and President of the Digital Health for Equitable Health Alliance. At Teva, she has been at the forefront of the launch and FDA approval of what might be the first digital inhalers for asthma, an issue that, just like allergies, affects People of Color severely. In the midst of 2020's COVID-19 peak of the pandemic and Atlanta's disruption triggered by George Floyd's murder, Tanisha felt inspired to do something that would positively impact her community; hence, she created the Digital Health for Equitable Health Alliance. This nonprofit membership organization brings together community-based medical institutions and organizations for the benefit of health equity through digital health. At DHEH, Tanisha seeks to make a difference in the representation of People of Color within the healthcare industry. The DHEH governance wants People of Color to make decisions regarding what happens within the organization. In terms of action, the DHEH focuses on advocating for policies that will close the gap in health equity. With the help of a team of attorneys, they scan policies that impact care delivery and are open for public comment, where they can give their input as experts in the intersection of health equity and digital health. The DHEH has grown significantly quickly and has already submitted several comments about public policies. The subjects they have given their opinion on so far are clinical trial diversity, the Pandemics Act, and the healthcare workforce. Regarding the latter, they believe digital health technologies not only support patients but also practicing providers and are tools that may help with the upcoming physician shortage. They're working for more POC representation within the clinical workforce, which will also drive equitable treatment. Tune in to learn more about the work the Digital Health for Equitable Health Alliance does for underserved communities from a policy perspective! --- Support this podcast: https://podcasters.spotify.com/pod/show/christopher-kunney/support

Haytham and Brian join the show to share the story of how Nationwide and Kinetic worked together initially as an investment, and then to build an MGA backed by Nationwide to help reduce worker injury through the application of Kinetic's IoT-based intervention that helps stop dangerous movements as they're happening. Their story is the first case in the new book in The Future of Insurance series, Volume III. The Collaborators. Brian Anderson is a partner at Nationwide and a former management associate in the company's Financial Leadership Rotation Program. Prior to joining Nationwide, Anderson was an intern at JPMorgan Chase in data analytics. Brian also worked as a venture fellow at Innovate Indiana Fund, where they served on the board of directors for Apex Therapeutics, Cause.it, and Fathom Voice. Anderson began their career as an intern in business development and M&A at Cephalon, Inc. (Teva Pharmaceuticals). Anderson has an NBA from the Kelley School of Business at Indiana University, and a B.A. in economics from Colorado College. Haytham Elhawary is cofounder and Chief Strategy Officer of KINETIC. Guided by a mission to help the front-line worker stay safe and healthy, he has led the development of a smart wearable device to reduce workplace injuries. KINETIC is reinventing workers compensation insurance by including its wearable technology as part of the policy. Elhawary holds a PhD in biomedical engineering from Imperial College London and a Mechanical Engineering degree from University of Navarra in Spain. His professional experience includes the development of medical robots at both Philips Electronics and Harvard Medical School. Prior to launching KINETIC in 2014, Elhawary served as Executive Director of the Zahn Innovation Center, a hardware startup incubator. Elhawary and his company are based out of New York, where he also writes theatre reviews and loves to do improvised comedy. Haytham Elhawary is co-founder and CEO of Kinetic They started in 2014 to build tech to reduce workplace injuries, primarily in frontline workers This was inspired by watching his mother, a nurse, get injured a lot from moving patients, and seeing the impact it had on her life Brian Anderson is a Partner at Nationwide Ventures They met Haytham in 2016, and were impressed by what the team had built Given Nationwide Venture's focus on things that connect to the company's mission, this appealed to them, as did how far the team at Kinetic got on a shoe string budget Nationwide chose to invest in Kinetic at that time, and see if there were opportunities for the insurance side of the business to work with Kinetic It was hard to get investment in the safety tech space because most VCs weren't thinking about that back then, making Nationwide a very rare and appropriate kind of investor for Kinetic when they met Brian talked about how, as investors, you need to be open to net new ideas if they want to find exciting new opportunities rather than letting your biases close you down to them The VC team introduced Kinetic to the Workers Comp team to look into a pilot opportunity, but the net result of the pilot wasn't strong, so Kinetic went off on their own and found self-insureds to test with and grow Not working out in that pilot wasn't a loss, though, as both teams learned a lot from it to see where it may not work, why, and what they can do instead, which was useful After 4 years and close to 35k workers wearing the device, Kinetic had data on dramatic reduction in injuries – 53% fewer injuries and over 70% fewer lost days from injuries – proving the impact their solution can have With that knowledge, they looked at how they can accelerate their impact, and learned about the MGA model as a way to sell insurance connected to the impact of their device That lead to Kinetic working with Nationwide E&S as the capacity for their insurance product The VC team opened the introduction, but it took the team at Kinetic being prepared, knowing their data, understanding what needed to be done, etc., to get the E&S team to get on board The two teams met in the summer of 2021, and were writing policies by December, which is incredibly fast They had talked to multiple carrier partners, but some things really stood out about Nationwide's approach Kinetic wanted to distribute the product themselves through their own broker relationships, and wanted to underwrite with their data They didn't want to do the more core insurance things like regulatory compliance or claims because they lacked the skills and people to do it right, and Nationwide was happy to manage those things They also were upfront about not knowing everything about what they're trying to do because it's the first time they were doing it, and Nationwide was open and understanding about it being a learning process for both of them There are always risks of a big company moving at its own speed, which can be too slow for a startup, and Nationwide was able to move very fast here The Venture team was helpful in trying to problem solve speed issues, but never forced anything or demanded it, instead working to be collaboratively internally Kinetic finished their first year 12x ahead of Nationwide's projections for premium, and the loss ratio is 20 points better than the industry number This shows that the idea is viable, the technology is helping protect people, and giving it away with the insurance is proving to be the right answer This episode is brought to you by The Future of Insurance thought leadership series (future-of-insurance.com) from Bryan Falchuk. Follow the podcast at future-of-insurance.com/podcast for more details and other episodes. Music courtesy of Hyperbeat Music, available to stream or download on Spotify, Apple Music, and Amazon Music and more.

About Manny Montalvo:Manny Montalvo is SVP, Head of Digital Health & Innovation at Teva Pharmaceuticals since September 2021. Manny is responsible for overseeing the US Respiratory business, the US commercial innovation work, and the US and GLOBAL DIGIHALER® franchise. Manny's digital health team at Teva is entirely homegrown and has pioneered a class of digital pharmaceutical devices - a rarity in the pharmaceutical industry. Manny's charge at Teva is to encourage the use of digital therapeutics as part of the healthcare experience, making it seamless for both the healthcare providers and the patients they serve. With over 20 years of life-science experience, Manny Montalvo has held leadership roles in both Sales and Marketing, working in numerous therapeutic areas in the US and global markets, as well as in R&D and Commercial Operations. Prior to assuming his current role, Manny Montalvo served as the Vice President of Global Digital Health Marketing & Commercial Analytics at Teva Pharmaceuticals where he set the strategic direction for Teva's biologic program and Digital Health Marketing and transformation of Teva's Global Commercial Analytics. Manny joined Teva in 2013 to lead its R&D Innovation program as Vice President of Global New Therapeutic Entities (NTE) Innovation where he focused on the evaluation of the latest drug delivery technologies and drug development, adding more than 15 new products to Teva's specialty portfolio. Before joining Teva, Manny held leadership positions with P&L responsibilities at Sanofi and Johnson & Johnson. During his tenure at Sanofi and J&J, Manny worked in a variety of commercial roles including consumer marketing, driving growth for a range of portfolios including diabetes, dermatology, cardiovascular and primary care.  Things You'll Learn:Two out of five medicines in your cabinet are likely from Teva.A platform business has a feedback loop with customers.To innovate, one has to have a collaborative space supported by management.Teva Pharmaceuticals is partnering with Rimidi and HealthSnap, integrating their data as a step closer to fulfilling their mission. The more patients on Teva's platform, the better the technology gets.About 40% of Teva's digital space workers did not come from the traditional pharma industry. Resources:Connect with and follow Manny Montalvo on LinkedIn.Follow Teva Pharmaceuticals on LinkedIn.Visit the Teva Pharmaceuticals Website!Discover DIGIHALER here!

Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc.

Subscriber-only episodeDr. Herman Weiss graduated Summa Cum Laude from Ramapo College of NJ with a degree In Philosophy and pursued a medical degree at The Ohio State University College of Medicine. After achieving his degree, he trained in Women's Health at Einstein College of Medicine Montefiore Medical Center/Jacobi Hospital in the Bronx, NY. He joined a vibrant practice in Long Island for eight-plus years and continued to have an entrepreneurial spirit and went back to school to complete his MBA from George Washington University. He co-founded and was the Chief Medical officer of a Biotech medical device company called FibroControl that dealt with minimally invasive techniques for women's health issues. He was recruited to become the Global Medical Director for Women's Health at Teva Pharmaceuticals an international giant in the pharma space. After five years at Teva he relocated to Boston where he was brought in to Juniper Pharmaceuticals to lead the Medical Affairs and Clinical Development departments, as VP. From there he was brought in as Interim CEO of Todos Medical focused on innovative solutions for early cancer detection. He developed, founded and launched the Master's Program for Commercialization and Entrepreneurship for Biotechnology at Yeshiva University in NYC. There he taught Fundamentals of Biotechnology to the Master students. He continued to teach various entrepreneurial courses at YU including Principles of Entrepreneurship and Founders Dilemmas. He recently launched his own startup focused on bringing medicine back to disease prevention and health maintenance specifically as it relates to Women's Health, where he is the CEO of Provation Life.Provation Life Supplement _ Weight Loss PCOS & More Amazon Website -https://provationlife.com/Education- https://education.provationlife.com/ Support the showAre YOU Feeling Stressed, Tired & Overall imbalanced? Enjoy a Free Mindful Steps!!https://mindfullyintegrative.mykajabi.com/pl/2147589400 Lets Work on Your Optimal Wellness Journey!Sign Up For Discovery Call://calendly.com/drdamarisg/30minEnjoy the Show and Get Bonus Episodes Subscribe For Just $4 a month Enjoy some of Our FREE Resources HereJoin Our Mindfully Integrative Private Facebook CommunityGet 15% off Pharmaceutical Grade Full Script Vitamins & Supplements

Please visit the Honestly HD website by going to www.honestlyhd.com Nina DeLucia is the Director of Consumer Marketing for AUSTEDO at Teva Pharmaceuticals.  She has worked in the life sciences industry for over 20 years for Pharmaceutical companies as well as for healthcare platforms such as WebMD and ePocrates.  She has a passion for patients and care partners and her goal is to represent their voices in her everyday work.  When she is not working, she can be found spending time with family and friends, training and racing for triathlons, or volunteering with her local youth group. She can be reached at nina.delucia@tevapharm.com.

This week I speak with Charlene Brisbane. She is currently a member of Dare to Imagine Church under the pastorship of Rev. Kevin Johnson. At Dare to Imagine, she is involved in community service and serves as an iGroup (small group) leader. In 2022, Charlene became vice president of the non-profit organization Clothed N Strength, whose mission is to help women overcome barriers to success who have recently returned to society after being incarcerated or who have suffered trauma. She is also the creator of a podcast with her daughter Shelby called Garage Conversations with Char, via which she hopes to engage, inform and inspire listeners. Charlene has a career in the biopharmaceutical industry that spans over 34 years which includes positions of increasing responsibility at Johnson and Johnson, GSK, and Teva Pharmaceuticals, where she currently is a Senior Director in Project Leadership and Strategy in R&D. Charlene believes that her foundation was laid spiritually, as well as, professionally at Trinity United Methodist Church where she accepted Christ in her life at an early age and was baptized. At Trinity, she was Chairperson of the Administrative Council, a Certified Lay Speaker, and a Sunday school teacher, as well as a member of United Methodist Women and The Inspirational Choir. Trinity was the place where she was given encouragement, responsibility, and the challenge always to strive to do her best. One of Charlene's favorite scriptures is Jeremiah 29:11: “For I know the plans I have for you declares the Lord, “plans to prosper you and not to harm you, plans to give you hope and a future.” She places her hope in God and acknowledges that all that she is is because of Him. We look at the life God has given Charlene, and even in the midst of the great loss of her husband, we see God working and providing for Char as a widow - The beautiful thread of God working is undeniable - You won't want to miss this episode you will be greatly encouraged!Dare to Imagine Church: https://d2ic.org/Garage Conversations with Char: https://garageconversationwithchar.com/Clothed N Strength: https://clothednstrength.org/Books referenced: Christians Get Depressed Too by David MurrayBroken Minds: Hope for Healing When You Feel Like You're "Losing It" by Steve & Robyn Bloem*Theme Music “Blessed time” by Ketsa

Synopsis: Jeremy Levin is the Chairman and CEO of Ovid Therapeutics, a company that develops medicines to treat patients with rare neurological conditions, including epilepsies and seizure-related disorders. Dr. Levin earned a PhD from Oxford and medical and surgical degrees from Cambridge before moving to the States in the late 1980s and eventually working in big pharma for companies such as Teva Pharmaceuticals and Bristol-Myers Squibb. He discusses how his formative years shaped his personal philosophy and mission to change the world for the better, the differences he experienced from running big pharma companies to early stage biotech startups, the science at Ovid and their pipeline, and his hopes for R&D in neurology over the next 10-20 years. Biography: Jeremy Levin, D.Phil, MB BChir, is chairman and chief executive officer of Ovid Therapeutics Inc. (NASDAQ: OVID), a company whose mission is to bring treatments to patients with rare neurological conditions. Dr. Levin is concurrently the chairman of Opthea (NASDAQ.OPT). Prior to founding Ovid, Dr. Levin was president and CEO of Teva Pharmaceutical Industries Ltd., (TLV: TEVA). Before Teva, Dr. Levin was a member of the executive committee Bristol-Myers Squibb Company (NYSE: BMY). In that capacity, he was the architect, lead and implementer of the String of Pearls Strategy, which transformed Bristol and facilitated the dawn and massive growth of the immuno-oncology revolution in the biopharmaceutical industry. Dr. Levin joined Bristol from Novartis (NYSE: NVS), where he was the global head of strategic alliances. He has served as a member of the board of directors of various public and private biopharmaceutical companies, including Biocon Ltd., (NSE: BIOCON), and is currently on the board of directors of Lundbeck (OMX: LUN). Dr. Levin also serves on the board and executive committee of the Biotechnology Innovation Organization (BIO) as the immediate past chairman. Dr. Levin was voted as one of the 25 most influential biotechnology leaders by Fierce Biotech, one of the top three biotechnology CEOs by The Healthcare Technology Report and one of the PharmaVoice100 CEOs in 2020. He was selected by Endpoints in 2021 as one of the 60 living pioneers of the industry. He is the recipient of the Albert Einstein Award for Leadership in Life Sciences and the B'nai B'rith Award for Distinguished Achievement. In June 2020, he edited and published the best seller “Biotechnology in the Time of Covid-19”. Dr Levin has been widely quoted and interviewed in national and international news outlets and life science industry-related publications. He believes that the role of leaders in business is to take a public stand on public policy matters as a core part of their business strategy and responsibility to shareholders, industry and society. He is committed to a public stance on key aspects of society and industry, including, but not limited to: encouraging immigration; policies that drive innovation; patient access to medicines; the principles of diversity, equity and inclusion; the primacy of medicine and science as the sole determinants to develop medical products; and the democratic right to vote for all citizens. Dr. Levin has practiced medicine at university hospitals in England, South Africa and Switzerland. Dr. Levin earned a First-Class Bachelor in Zoology, winning the University Prize, and subsequently, was awarded a master's degree and doctorate in chromatin structure, at the University of Oxford. Thereafter, he earned his medical and surgical degrees from the University of Cambridge, where he won the Kermode Prize for his work on Captopril.

About the Episode In this podcast, you will hear a panel discussion moderated by Dr Sheela Kolluri, Teva Pharmaceuticals, from the 2022 Chief Medical Officer Summit 360° regarding what CMOs need to know about statistics, strategies for clinical development, strengths and weaknesses of complex trial designs and how to maximize the use of your statisticians. Panelists include: Marcia Levenstein, ScD, MBE, VivliNatasha Mühlemann, MD, MBA, CytelJeffrey Bornstein, MD, Eledon Pharmaceuticals To learn more about the upcoming 2023 CMO Summit 360°, please visit: www.theconferenceforum.org

In this special episode of Molecule to Market, we go back inside the global drug development space with Marcelo Bigal, President and CEO, of Ventus Therapeutics, and Versant Venture Partner, who shares his journey from being a neurologist to taking a drug to market when he became part of Teva Pharmaceuticals and now is a CEO. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Marcelo, covering:  What it feels like to take a drug from the laboratory to market and what really goes into that process. The company's phenomenal attitude toward patients and how this is exemplified in its drug development.  The incredible story of the company he joined and how 14 months after a fundraiser it was acquired by Teva Pharmaceuticals for $825M. The current state of the capital market and where future opportunities may lie for the business.  The challenging area of drug development in biotechnology over the last three years.  Marcelo brings more than 13 years of pharma experience with a focus on urology spanning r&d, medical and scientific affairs. He has extensive experience in leading large and small scientific groups, including multiple leadership roles in industry, including the Chief Scientific Officer at Teva as well as Chief Medical Officer at Teva and Purdue. Prior to his work in the pharma sector, Marcelo was a faculty member of the Albert Einstein College of Medicine, Department of Neurology, as well as the director of research at the New England Centre for headache.  He has authored no fewer than 330 papers in peer-reviewed journals, edited six books in urology and is the recipient of multiple awards and recognitions in the field. Marcelo holds a medical doctorate degree from the College of Medicine at the University of Sao Paulo, Brazil, where he obtained a master's in science and a PhD in neurosciences. He completed his postdoctoral research at the New England Centre for headache.

Despite treasury being an international language, there are cultural shifts that can be difficult to navigate. We go through our Treasury Career Corner archives again for this insightful episode with Stephen Harper, currently SVP Global Treasury, Insurance & ERM at Teva Pharmaceuticals. Stephen appeared on the show in 2020 to discuss his move from banking to international treasury, what led him to these decisions and to outline the cultural shifts that pose challenges in a global treasury career. Stephen Harper is a seasoned senior finance professional with over 20 years of experience across four continents. He has a wealth of experience in corporate finance, business strategy, M&A, risk management, cash management, pooling and netting, investor relations and many more areas. Starting with Merck in 1991 as Benelux/Nordic Treasurer, his career has seen him work with Flextronics International as Vice President & Corporate Treasurer, then in a similar role with Amcor Limited. He later moved to The Nuance Group in Switzerland in 2013 as Head of Treasury & Investor Relations, before switching to Australia with Pact Group. After three years of self-employment, he joined NIDEC EUROPE B.V. as General Manager Treasury Europe in March 2019 in Almere, Netherlands, before taking on his current role in Tel Aviv, Israel, with Teva Pharmaceuticals. On the podcast we discuss… Stephen's transition from banking into treasury Why Stephen was keen to leave the UK to grow his career The key differences between UK and international treasury How treasurers can prepare for a crisis The evolution of treasury and Stephen's predictions Preparing to be a treasury professional post-COVID You can connect with Stephen Harper on https://www.linkedin.com/in/stephen-harper-4004b439/ (LinkedIn.) Are you interested in pursuing a career within Treasury? Whether you've recently graduated, or you want to search for new job opportunities to help develop your treasury career, The Treasury Recruitment Company can help you in your search for the perfect job. https://treasuryrecruitment.com/jobs (Find out more here). Or, send us your CV and let us help you in your next career move! If you're enjoying the show please rate and review us on whatever podcast app you listen to us on, for Apple Podcasts https://podcasts.apple.com/gb/podcast/the-treasury-career-corner/id1436647162#see-all/reviews (click here)!

BA.5 is now the most dominant variant showing up in wastewater in the South Bay, San Francisco, Silicon Valley, Sacramento and elsewhere.  The latest data from researchers who study sewage shows clues into how COVID-19 is spreading across the Bay Area.  Science Editor Kevin Stark, KQED There's a 25% increase in COVID hospitalizations in Los Angeles County. Health officials say on Thursday LA County could move into the CDC's high risk category for COVID community spread due to high hospitalizations. Reporter Jackie Fortier, The California Report The FDA has revised its Emergency Use Authorization to let licensed pharmacists prescribe Paxlovid, the treatment given to those at risk of serious illness from COVID. Reporter Carly Severn, The California Report City attorney David Chiu announced that Allergan and Teva Pharmaceuticals agreed to pay $34 million-dollars in cash, and another $20 million dollars worth of Narcan, a treatment for opioid overdose.  Walgreens is the only remaining defendant in the case; their lawyers are set to give closing arguments today.  Californians who are in mental distress and thinking about suicide will be able to call, or text, a new three digit number (9-8-8) to get help.  But if they call, will someone pick-up the line?  Reporter Saul Gonzalez, The California Report   Starting on Saturday, Californians who are in mental distress and thinking about suicide will be able to call, or text, a new three digit number to get help. But if they call, will someone pick-up the line? Reporter Saul Gonzalez, The California Report AB 1594 allows state and local governments, and private individuals, to sue gun-makers and sellers for damage caused by their products. Newsom signed legislation last month – adding restrictions on hard to trace ghost guns, and restricting ads for firearms aimed at minors. Politics Editor Scott Shafer, KQED Next week, Dodger Stadium will host the Major League Baseball... All Star Game. But, unions representing the stadium's 15-hundred food and beverage workers say they've got enough votes to authorize a strike. All Star festivities kick off this weekend with MLB's Futures Game. The union is hoping to hear from Levy Restaurants before the start of the game.

For Felipe Sotelo, it's all about priorities. That's why Dad & Husband are the titles on his LinkedIn profile. It's also why he now believes demand forecast agility is more important than accuracy in the post-pandemic world of supply chain disruptions. On this episode of The Health Pulse, positive thinker, business reinvention leader and writer Sotelo joins host Alex Maiersperger to share his insights as a supply chain leader for organizations including Johnson & Johnson, Teva Pharmaceuticals and PepsiCo. Forecast accuracy can never be perfect, and in a scenario full of disruptions, Sotelo argues that it's more important to focus on agility and speed so that organizations can respond more effectively to disruptions. In his opinion, prioritization plays a big role, and the organizations that succeed are those that have both a strong leadership strategy and investment in technology and analytics to drive insights into keeping the strategy on track. The main focus now is regulating supply chains to ensure essential equipment is available. And, the new normal will prioritize both cost efficiency and reliability over cost efficiency alone.When asked about a light at the end of the tunnel for pandemic-related disruption, Sotelo predicts we won't see it before 2024. But, that doesn't keep him from being optimistic about the role of supply chain leaders in shaping a better, more sustainable future. 

Reporting from the floor of the Medical Affairs Professionals Society (MAPS) Global Annual Meeting, this podcast series features interviews with industry leaders, focusing in on the impact and value of Medical Affairs today, where the function is heading and how we are going to get there.It's no question that Medical Affairs has historically struggled to show value and impact within its organization. In this second episode of the series, Arshi Gupta, Managing Director, Medical Affairs at Syneos Health and Deb Crawford, Director, MSL Team at Teva Pharmaceuticals discuss the intricacies  involved in measuring what seems, well, immeasurable.Be sure to listen to the other episodes in this series here.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you're hearing?  Be sure to rate and review us!  We want to hear from you!  If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Attorney General Patrick Morrisey (R-WV) wins big in court over opioid manufacturing companies, Allergan Financial LLC and Teva Pharmaceuticals. The Attorney General is now focusing his fight against the Biden Administration as it regards the U.S. Securities and Exchange Commission that proposed a new 'ESG rule' that encroaches on the privacy and work of farmers while weaponizing their bureaucracy into an 'environmental regulator.' See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Beth Borowsky is an Executive Director and Senior Global Program Clinical Head in Neuroscience at Novartis Pharmaceutical Corporation, where she has been since 2018. Prior to Novartis, Beth spent 12 years doing clinical research and development for Huntington's Disease, first at CHDI Foundation, where she was the Director of Translational Medicine, and then at Teva Pharmaceuticals, where she was a Senior Clinical Development Director. Prior to that, Beth spent 13 years in CNS drug discovery and development with Sanofi-Aventis and Synaptic Pharmaceuticals. Beth received a BS in Psychology and Neurobiology from Rutgers University, and a PhD in Pharmacology from Duke University Medical Center. She completed her post-doctoral training at the National Institute of Mental Health

Everyone wants to get into mining these days. The extractive industries have seen a flurry of interest as the rush to decarbonize our economies sparks a race to control the metals those low-carbon technologies need to work. We discuss the ESG paradox this creates: on the one hand, mining is a fundamentally challenging sector when it comes to ESG and on the other hand for renewable energy to be a feasible solution to fossil fuels, we need batteries. Then we discuss a sustainability bond issued by Teva Pharmaceuticals with some of its provisions tied to both better access to healthcare and lower greenhouse gas emissions.Host: Mike DisabatoGuests: Samuel Block, MSCI ESG Research; Namita Nair, MSCI ESG Research